170 related articles for article (PubMed ID: 31947581)
1. Development and Optimization of a GMP-Compliant Manufacturing Process for a Personalized Tumor Lysate Dendritic Cell Vaccine.
Boudousquié C; Boand V; Lingre E; Dutoit L; Balint K; Danilo M; Harari A; Gannon PO; Kandalaft LE
Vaccines (Basel); 2020 Jan; 8(1):. PubMed ID: 31947581
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells.
Eyrich M; Schreiber SC; Rachor J; Krauss J; Pauwels F; Hain J; Wölfl M; Lutz MB; de Vleeschouwer S; Schlegel PG; Van Gool SW
Cytotherapy; 2014 Jul; 16(7):946-64. PubMed ID: 24831836
[TBL] [Abstract][Full Text] [Related]
3. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
Sarivalasis A; Boudousquié C; Balint K; Stevenson BJ; Gannon PO; Iancu EM; Rossier L; Martin Lluesma S; Mathevet P; Sempoux C; Coukos G; Dafni U; Harari A; Bassani-Sternberg M; Kandalaft LE
J Transl Med; 2019 Nov; 17(1):391. PubMed ID: 31771601
[TBL] [Abstract][Full Text] [Related]
4. An accelerated, clinical-grade protocol to generate high yields of type 1-polarizing messenger RNA-loaded dendritic cells for cancer vaccination.
Brabants E; Heyns K; De Smet S; Devreker P; Ingels J; De Cabooter N; Debacker V; Dullaers M; VAN Meerbeeck JP; Vandekerckhove B; Vermaelen KY
Cytotherapy; 2018 Sep; 20(9):1164-1181. PubMed ID: 30122654
[TBL] [Abstract][Full Text] [Related]
5. Clinical scale electroloading of mature dendritic cells with melanoma whole tumor cell lysate is superior to conventional lysate co-incubation in triggering robust in vitro expansion of functional antigen-specific CTL.
Wolfraim LA; Takahara M; Viley AM; Shivakumar R; Nieda M; Maekawa R; Liu LN; Peshwa MV
Int Immunopharmacol; 2013 Mar; 15(3):488-97. PubMed ID: 23474736
[TBL] [Abstract][Full Text] [Related]
6. An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastoma.
Nava S; Dossena M; Pogliani S; Pellegatta S; Antozzi C; Baggi F; Gellera C; Pollo B; Parati EA; Finocchiaro G; Frigerio S
PLoS One; 2012; 7(12):e52301. PubMed ID: 23284979
[TBL] [Abstract][Full Text] [Related]
7. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
8. Automated Good Manufacturing Practice-compliant generation of human monocyte-derived dendritic cells from a complete apheresis product using a hollow-fiber bioreactor system overcomes a major hurdle in the manufacture of dendritic cells for cancer vaccines.
Uslu U; Erdmann M; Wiesinger M; Schuler G; Schuler-Thurner B
Cytotherapy; 2019 Nov; 21(11):1166-1178. PubMed ID: 31668486
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
[TBL] [Abstract][Full Text] [Related]
10. A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model.
Mookerjee A; Graciotti M; Kandalaft LE; Kandalaft L
Bioimpacts; 2018; 8(3):211-221. PubMed ID: 30211081
[No Abstract] [Full Text] [Related]
11. Safe and Reproducible Preparation of Functional Dendritic Cells for Immunotherapy in Glioblastoma Patients.
Nava S; Lisini D; Pogliani S; Dossena M; Bersano A; Pellegatta S; Parati E; Finocchiaro G; Frigerio S
Stem Cells Transl Med; 2015 Oct; 4(10):1164-72. PubMed ID: 26273063
[TBL] [Abstract][Full Text] [Related]
12. Automated closed-system manufacturing of human monocyte-derived dendritic cells for cancer immunotherapy.
Erdmann M; Uslu U; Wiesinger M; Brüning M; Altmann T; Strasser E; Schuler G; Schuler-Thurner B
J Immunol Methods; 2018 Dec; 463():89-96. PubMed ID: 30266448
[TBL] [Abstract][Full Text] [Related]
13. Closing the manufacturing process of dendritic cell vaccines transduced with adenovirus vectors.
Gulen D; Abe F; Maas S; Reed E; Cowan K; Pirruccello S; Wisecarver J; Warkentin P; Northam M; Turken O; Coskun U; Senesac J; Talmadge JE
Int Immunopharmacol; 2008 Dec; 8(13-14):1728-36. PubMed ID: 18793758
[TBL] [Abstract][Full Text] [Related]
14. Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens.
Iranpour S; Nejati V; Delirezh N; Biparva P; Shirian S
J Exp Clin Cancer Res; 2016 Oct; 35(1):168. PubMed ID: 27782834
[TBL] [Abstract][Full Text] [Related]
15. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
[TBL] [Abstract][Full Text] [Related]
16. Tumor lysate-loaded Bacterial Ghosts as a tool for optimized production of therapeutic dendritic cell-based cancer vaccines.
Dobrovolskienė N; Pašukonienė V; Darinskas A; Kraśko JA; Žilionytė K; Mlynska A; Gudlevičienė Ž; Mišeikytė-Kaubrienė E; Schijns V; Lubitz W; Kudela P; Strioga M
Vaccine; 2018 Jul; 36(29):4171-4180. PubMed ID: 29895501
[TBL] [Abstract][Full Text] [Related]
17. Antigen-loaded dendritic cells triggers a specific cytotoxic T lymphocytes immune response against hepatocellular carcinoma: in vitro study.
El-Ashmawy NE; El-Zamarany EA; Khedr EG; El-Bahrawy HA; El-Feky OA
Clin Transl Oncol; 2019 May; 21(5):636-645. PubMed ID: 30368725
[TBL] [Abstract][Full Text] [Related]
18. PGE
Nava S; Lisini D; Frigerio S; Pogliani S; Pellegatta S; Gatti L; Finocchiaro G; Bersano A; Parati EA
Pharmaceutics; 2020 Mar; 12(3):. PubMed ID: 32131407
[TBL] [Abstract][Full Text] [Related]
19. Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists.
Lövgren T; Sarhan D; Truxová I; Choudhary B; Maas R; Melief J; Nyström M; Edbäck U; Vermeij R; Scurti G; Nishimura M; Masucci G; Karlsson-Parra A; Lundqvist A; Adamson L; Kiessling R
Cancer Immunol Immunother; 2017 Oct; 66(10):1333-1344. PubMed ID: 28601925
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]